Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.48 |
| ▸ | HTR3B | O95264 | 4/20 | 0.48 |
| ▸ | HTR3A | P46098 | 4/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9090858 | 0.98 | SIGMAR1 (0.47) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8411629 | 0.98 | SIGMAR1 (0.47) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| Succinic Acid SCHEMBL1360757 | 0.86 | SIGMAR1 (0.44) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| Succinic Acid SCHEMBL19644019 | 0.86 | SIGMAR1 (0.44) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6185118 | 0.85 | ADRB1 (0.49) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9650536 | 0.84 | CYP2B6 (0.46) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2491597 | 0.82 | CHRM2 (0.40) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7769823 | 0.82 | KCNN4 (0.48) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2491431 | 0.82 | ADRB1 (0.49) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27814643 | 0.82 | POLB (0.54) | SIGMAR1CYP2D6ALDH1A1HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529043-A1 | NOVEL PROCESS | Biovitrum AB (SE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| JP-11005786-A | — | — | None | — | — | JP | disclosed |
| WO-2024137495-A9 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024137495-A1 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | NAVINTA, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| EP-4219717-A2 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-4876257-A | 6-Substituted purinyl piperazine derivatives useful as cardiotonic and antiarrhythmic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0331511-A1 | 6-Substituted purinyl piperazine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0331510-A2 | 4-Substituted pyrazolo[3,4-d]pyrimidine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330263-A1 | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4576749-A | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4382934-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0010398-B1 | ISATIN DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-04-27 | — | — | EP | disclosed |
| EP-0010398-A1 | Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | FIP1L1, CYP3A4, FOS | SIGMAR1 3339/4885HTR3E 3591/4885HTR3B 2786/4885 |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, DCLRE1B | SIGMAR1 4151/4885HTR3E 4104/4885HTR3B 3765/4885 |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | SIGMAR1 4151/4885HTR3E 4104/4885HTR3B 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.